Increased mortality in patients with acute critical illness due to complications following open heart surgery , abdominal surgery or multiple accidental trauma , or those with acute respiratory failure has been reported after treatment with pharmacologic amounts of somatropin [see CONTRAINDICATIONS ]. Two placebo-controlled clinical trials in non-growth hormone deficient adult patients (n=522) with these conditions in intensive care units revealed a significant increase in mortality (42% vs. 19%) among somatropin-treated patients (doses -8 mg/day) compared to those receiving placebo. The safety of continuing somatropin treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. Therefore, the potential benefit of treatment continuation with somatropin in patients experiencing acute critical illnesses should be weighed against the potential risk.
Monday and things picked up a bit after the slow weekend. Dr. Altouri led a delegation into my room at about 9:30 am – himself, Dr. Drouin, Tiffany the Pharmacist, one of the Arabic female doctors who Pat can always seem to identify but all look exactly the same to me, especially with their masks on, and a fifth person that I never really got to connect with. He was pleased. My oxygen demands are diminishing, should be down to zero in a day or two. The results from the bronchoscopy continue to be negative so there appear to be no infections other than the viral one that is causing my cold and can only be defeated by Doctor and Nurse Time, though it will take time because of my compromised immune system. He doesn’t see much point in me staying in the hospital but that is a decision that will be made by Dr. Buchan, my infectious disease doctor, who will have to decide when I can be unhooked from the IV pole. So that was all good news. Pat arrived just as the delegation was exiting but she had a chance to talk to Dr. Altouri who has become quite pally with her now and he brought her up to date.